The price of the voucher depends on supply and demand. The voucher’s commercial value derives from three factors: shifting sales earlier, competitive benefits from earlier entry relative to competitors, and longer effective patent life due to earlier entry. Top-selling treatments can yield billions in sales each year, so being approved months earlier can be worth hundreds of millions of dollars to the voucher holder (Ridley et al. 2006; Ridley and Régnier 2016).
Estimates are based on public and private sources.
This web page is maintained by David Ridley, one of the authors of the priority review voucher program.